Ocera Therapeutics Inc. (NASDAQ:OCRX)’s share price dropped 6% on Tuesday . The stock traded as low as $2.30 and last traded at $2.33, with a volume of 421,371 shares traded. The stock had previously closed at $2.48.

Separately, Zacks Investment Research upgraded Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price on the stock in a research report on Tuesday, August 9th.

The stock’s market cap is $51.57 million. The company has a 50-day moving average price of $2.40 and a 200-day moving average price of $2.64.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/ocera-therapeutics-inc-ocrx-stock-price-down-6.html

Ocera Therapeutics (NASDAQ:OCRX) last issued its quarterly earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.02. Ocera Therapeutics had a negative return on equity of 97.93% and a negative net margin of 23,955.08%. Analysts anticipate that Ocera Therapeutics Inc. will post ($1.34) earnings per share for the current year.

Several institutional investors have recently modified their holdings of OCRX. Deerfield Management Co. boosted its position in shares of Ocera Therapeutics by 660.9% in the second quarter. Deerfield Management Co. now owns 572,893 shares of the biopharmaceutical company’s stock valued at $1,088,000 after buying an additional 497,600 shares during the period. Sabby Management LLC boosted its position in shares of Ocera Therapeutics by 6.3% in the second quarter. Sabby Management LLC now owns 424,035 shares of the biopharmaceutical company’s stock worth $806,000 after buying an additional 25,000 shares during the last quarter. Bridgeway Capital Management Inc. boosted its position in shares of Ocera Therapeutics by 55.2% in the second quarter. Bridgeway Capital Management Inc. now owns 210,860 shares of the biopharmaceutical company’s stock worth $401,000 after buying an additional 75,000 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Ocera Therapeutics by 1.2% in the second quarter. Vanguard Group Inc. now owns 408,835 shares of the biopharmaceutical company’s stock worth $777,000 after buying an additional 4,900 shares during the last quarter. Finally, Vivo Capital LLC bought a new position in shares of Ocera Therapeutics during the first quarter worth about $451,000. Institutional investors own 36.03% of the company’s stock.

About Ocera Therapeutics

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

5 Day Chart for NASDAQ:OCRX

Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.